# SERENA-6 (NCT04964934)

> Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04964934
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: ER-Positive HER2-Negative Breast Cancer
- Interventions: AZD9833; AZD9833 Placebo; Anastrozole; Anastrozole placebo; Letrozole; Letrozole placebo; Palbociclib; Abemaciclib; Luteinizing hormone-releasing hormone (LHRH) agonist; Ribociclib
- Enrollment: 315
- Primary outcome: Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)

## Commentary we found

- X threads: 239
- YouTube: 220
- Podcasts: 146
- X videos: 13

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=serena-6-nct04964934

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04964934", "email": "<work email>"}; the inbox owner confirms by the emailed link.